OBJECTIVE: Compared with every-3-week paclitaxel (q3T) plus carboplatin, dose-dense weekly paclitaxel (ddT) plus carboplatin improved the survival of ovarian cancer patients. We performed a cost analysis comparing these two regimens. METHODS: Using a Markov decision model, an acceptable incremental cost-effectiveness ratio (ICER) per progression-free life-year saved (PFLYS) was estimated. Cost of drugs, growth colony-stimulating factors, and transfusions were derived from Medicare reimbursement data. Survival and rates of complications were estimated based on the clinical trial. RESULTS: Using a body weight and surface area of an average woman age 63, the estimated cost per cycle of ddT was $107 vs. $80 for q3T. The costs per cycle of combination chemotherapy including treatment administration were $873 for ddT and $535 for q3T. With a median progression-free survival (PFS) of 28 months with ddT vs. 17.2 months with q3T, the ICER was $5809 per PFLYS for ddT compared with q3T arm. Using a maximum ICER of $100,000 per LYS as cost-effective threshold, the ddT regimen was cost-effective. The ICER was most sensitive to the hazard rate for difference in PFS between the two regimens. A 4-month difference in PFS resulted in a $1200 change of ICER per PFLYS. The ICER was also sensitive to overall survival difference, rate of hematological toxicity, and rate of discontinuation. CONCLUSIONS: In this economic model, dose-dense weekly paclitaxel is a cost-effective treatment option for advanced ovarian cancer.
RCT Entities:
OBJECTIVE: Compared with every-3-week paclitaxel (q3T) plus carboplatin, dose-dense weekly paclitaxel (ddT) plus carboplatin improved the survival of ovarian cancerpatients. We performed a cost analysis comparing these two regimens. METHODS: Using a Markov decision model, an acceptable incremental cost-effectiveness ratio (ICER) per progression-free life-year saved (PFLYS) was estimated. Cost of drugs, growth colony-stimulating factors, and transfusions were derived from Medicare reimbursement data. Survival and rates of complications were estimated based on the clinical trial. RESULTS: Using a body weight and surface area of an average woman age 63, the estimated cost per cycle of ddT was $107 vs. $80 for q3T. The costs per cycle of combination chemotherapy including treatment administration were $873 for ddT and $535 for q3T. With a median progression-free survival (PFS) of 28 months with ddT vs. 17.2 months with q3T, the ICER was $5809 per PFLYS for ddT compared with q3T arm. Using a maximum ICER of $100,000 per LYS as cost-effective threshold, the ddT regimen was cost-effective. The ICER was most sensitive to the hazard rate for difference in PFS between the two regimens. A 4-month difference in PFS resulted in a $1200 change of ICER per PFLYS. The ICER was also sensitive to overall survival difference, rate of hematological toxicity, and rate of discontinuation. CONCLUSIONS: In this economic model, dose-dense weekly paclitaxel is a cost-effective treatment option for advanced ovarian cancer.
Authors: Insiya B Poonawalla; Rohan C Parikh; Xianglin L Du; Helena M VonVille; David R Lairson Journal: Pharmacoeconomics Date: 2015-11 Impact factor: 4.981
Authors: Natalie Yl Ngoi; Nicholas Lx Syn; Robby M Goh; Boon Cher Goh; Ruby Yun-Ju Huang; Yu Yang Soon; Elizabeth James; Adrian Cook; Andrew Clamp; David Sp Tan Journal: Cochrane Database Syst Rev Date: 2022-02-21
Authors: John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk Journal: N Engl J Med Date: 2016-02-25 Impact factor: 91.245
Authors: John K Chan; Thomas J Herzog; Lilian Hu; Bradley J Monk; Tuyen Kiet; Kevin Blansit; Daniel S Kapp; Xinhua Yu Journal: Oncologist Date: 2014-04-10
Authors: Chen-Yu Huang; Min Cheng; Na-Rong Lee; Hsin-Yi Huang; Wen-Ling Lee; Wen-Hsun Chang; Peng-Hui Wang Journal: Int J Environ Res Public Health Date: 2020-03-26 Impact factor: 3.390